Q-linea AB's revenue for the
three
months ended in Mar. 2026 was kr2.03 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr9.44 Mil.
Q-linea AB's Revenue per Share for the
three
months ended in Mar. 2026 was kr0.11.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.03.
Warning Sign:
Q-linea AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Q-linea AB was -60.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -69.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -22.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, Q-linea AB's highest 3-Year average Revenue per Share Growth Rate was 132.90% per year. The lowest was -69.40% per year. And the median was 65.10% per year.
Q-linea AB (CHIX:QLINEs) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Q-linea AB Revenue Related Terms
Q-linea AB Revenue Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Q-linea AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Revenue distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr9.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINES) has a Revenue of kr9.44 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Q-linea AB and its competitors.
Is Q-linea AB's Revenue too high?
Q-linea AB's current Revenue is kr9.44 Mil. Overall, Q-linea AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Revenue compare to ABT and SYK?
Q-linea AB's Revenue of kr9.44 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Q-linea AB and its competitors. Q-linea AB's current Revenue is kr9.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Revenue of kr9.44 Mil. The stock's GF Value™ is kr1,921.76, compared to a current price of kr1,610.00 — trading 16.2% below its estimated fair value. The current Revenue is kr9.44 Mil. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Revenue is kr9.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 16.2% below its estimated GF Value™ of kr1,921.76.
Key valuation signals for CHIX:QLINES:
Revenue: kr9.44 Mil
GF Value™: kr1,921.76 vs. price of kr1,610.00 (16.2% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score
Get the complete analysis for CHIX:QLINES
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
